The majority of cancer-related deaths occur subsequent to the development of metastatic disease. This highly lethal disease stage is associated with the presence of circulating tumor cells (CTCs). These rare cells have been demonstrated to be of clinical significance in metastatic breast, prostate, and colorectal cancers. The current gold standard in clinical CTC detection and enumeration is the FDA-cleared CellSearch system (CSS). This manuscript outlines the standard protocol utilized by this platform as well as two additional adapted protocols that describe the detailed process of user-defined marker optimization for protein characterization of patient CTCs and a comparable protocol for CTC capture in very low volumes of blood, using standard CSS reagents, for studying in vivo preclinical mouse models of metastasis. In addition, differences in CTC quality between healthy donor blood spiked with cells from tissue culture versus patient blood samples are highlighted. Finally, several commonly discrepant items that can lead to CTC misclassification errors are outlined. Taken together, these protocols will provide a useful resource for users of this platform interested in preclinical and clinical research pertaining to metastasis and CTCs.
Introduction
In 2013 it is estimated that 580,350 individuals will die from cancer and that 1,660,290 new cases of this disease will be diagnosed in the United States alone 1 . The majority of these deaths occur subsequent to the development of metastatic disease 2 . The current lack of effective therapies in treating metastases and a limited understanding of the metastatic cascade makes this stage of disease highly lethal. The presence of circulating tumor cells (CTCs) within the bloodstream have been demonstrated to correlate with metastatic disease 3 . These cells are extremely rare and their detection is indicative of overall survival in metastatic breast 4 , prostate 5 , and colorectal 6 cancer. In these patients, the presence of ≥5 (breast and prostate) or ≥3 (colorectal) CTCs in 7.5 ml of blood is indicative of poorer prognosis when compared to those patients with fewer or no detectable CTCs in the same blood volume. In addition, the change in CTC number during or after therapeutic intervention has been demonstrated to be useful as a predictor of treatment response, often sooner than currently utilized techniques [7] [8] [9] [10] .
It has been estimated that, in metastatic cancer patients, CTCs occur at a frequency of approximately 1 CTC per 10 5 -10 7 blood mononuclear cells and in patients with localized disease, this frequency may be even lower (~1 in 10 8 ). The rare nature of these cells can make it difficult to accurately and reliably detect and analyze CTCs 11 . Several methods (reviewed previously [12] [13] [14] ) have been utilized to enrich and detect these cells by exploiting properties that differentiate them from surrounding blood components. In general, CTC enumeration is a two-part process that requires both an enrichment step and a detection step. Traditionally, enrichment steps rely on differences in physical properties of CTCs (cell size, density, deformability) or on protein marker expression (i.e. epithelial cell adhesion molecule [EpCAM] , cytokeratin [CK]). Following enrichment, CTC detection can be performed in a number of different ways, the most common of which are nucleic acid-based assays and/or cytometric approaches. Each of these strategies are unique, having distinct advantages and disadvantages, however they all lack standardization; a necessity for entrance into the clinical setting. The CellSearch system (CSS) was therefore developed to provide a standardized method for the detection and enumeration of rare CTCs in human blood using fluorescence microscopy and antibody-based techniques [4] [5] [6] . This platform is currently considered the gold standard in CTC enumeration and is the only technique approved by the U.S. Food and Drug Administration (FDA) for use in the clinic The analysis instrument is used to scan prepared samples using different fluorescence filters, each optimized to the appropriate fluorescent particle, using a 10X objective lens. CTCs are identified as cells that are bound by anti-EpCAM, anti-pan-CK-phycoerythrin (PE) (CK8, 18, and 19) , and the nuclear stain 4',6-diamidino-2-phenylindole (DAPI). Conversely, contaminating leukocytes are identified as cells that are bound by anti-CD45-allophycocyanin (APC) and DAPI. Following scanning, computer-defined potential tumor cells are presented to the user. From these images, the user must employ qualitative analysis using the defined parameters and differential staining discussed above to determine which events are CTCs.
In addition to providing a standardized method for CTC enumeration, the CSS allows for molecular characterization of CTCs based on protein markers of interest. This interrogation can be performed at the single-cell level, using a fluorescein isothiocyanate (FITC) fluorescence channel not required for CTC identification 16 . Although this platform provides the capacity for molecular characterization, the detailed process of protocol development and optimization is not well-defined. Three commercially available markers have been developed by the manufacturer for use with the CSS, including epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and insulin-like growth factor 1 receptor (IGF-1R). HER2 analysis, in combination with the CSS, has been utilized by several groups to illustrate the potential for CTC characterization to inform clinical decision-making and to potentially change existing treatment guidelines. For example, Fehm et al. 17 demonstrated that approximately one third of breast cancer patients with HER2-primary tumors had HER2 + CTCs. In addition, Liu et al. 18 recently reported that up to 50% of patients with HER + metastatic breast cancer did not have HER2 + CTCs. Herceptin, a HER2 receptor interfering monoclonal antibody demonstrated to greatly benefit patients whose tumors express sufficient levels of HER2, is a commonly utilized treatment for patients with HER2 + primary tumors [19] [20] [21] . However, these studies suggest that Herceptin may be being sub-optimally utilized and that CTC characterization may aid in predicting treatment response. Ultimately, CTC characterization may have the potential to improve personalized care.
CTC research is unique in that it has largely utilized a bedside-to-benchtop approach. This method, unlike benchtop-to-bedside research, which can often take years to impact patient care, has allowed CTCs quick entry into the clinical setting. However, physicians are hesitant to use results from CTC analysis in patient treatment decision-making due to a lack of understanding of their underlying biology. Therefore appropriate preclinical mouse models of metastasis and complementary CTC analysis techniques must be utilized in order to investigate these outstanding questions. In general, there are two types of preclinical models used to study the metastatic cascade, (1) spontaneous metastasis models, which allow for the study of all the steps in the metastatic cascade, and (2) experimental metastasis models, which only allow for the study of later steps in the metastatic process such as extravasation and secondary tumor formation 22 . Spontaneous metastasis models, involve tumor cell injections into appropriate orthotopic locations (e.g. injection of prostate cancer cells into the prostate gland for the study of prostate cancer). Cells are then given time to form primary tumors and spontaneously metastasize to secondary sites such as the bone, lung, and lymph nodes. In contrast, experimental metastasis models involve direct injection of tumor cells into the bloodstream (e.g. via tail vein or intracardiac injection to target cells to specific locations) and therefore skip the initial steps of intravasation and dissemination to secondary organs 22 . Thus far the majority of CTC analysis in in vivo model systems has been performed using either cytometry-based 23 or adapted human-based CTC techniques (e.g. AdnaTest) 24 . Although useful, none of these techniques adequately reflect CTC enumeration using the gold standard CSS. Based on the clinical approval, standardized nature, and widespread usage of the CSS, the development of a CTC capture and detection technique for in vivo modeling that utilizes equivalent sample preparation, processing, and identification criteria would be advantageous as results would be comparable to those obtained from patient samples. However, due to the volume requirements of the preparation instrument it is not possible to process small volumes of blood using this automated platform. In addition, previous work by Eliane et al. 25 has demonstrated that contamination of samples with mouse epithelial cells (which also meet the standard CTC definition [EpCAM
) can lead to misclassification of mouse squamous epithelial cells as CTCs. To address these issues an adapted technique that allows the utilization of the CSS CTC kit reagents combined with a manual isolation procedure was developed. The addition of a FITC labeled human leukocyte antigen (HLA) antibody to the assay allows human tumor cells to be distinguished from mouse squamous epithelial cells.
This manuscript describes the standard, commercially developed and optimized CSS protocol for processing patient blood samples and common pitfalls that may be encountered, including discrepant items that can lead to CTC misclassification errors. In addition, customization of the CSS assay to examine user-defined protein characteristics of captured CTCs and a comparable adapted CSS technique that allows for the enrichment and detection of CTCs from small volumes of blood in preclinical mouse models of metastasis are described.
Protocol
All human studies described in this manuscript were carried out under protocols approved by Western University's Human Research Ethics Board. All Animal studies were conducted in accordance with the recommendations of the Canadian Council on Animal Care, under protocols approved by the Western University Animal Use Subcommittee.
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3. Using a disposable 10 ml pipette and automated pipettor, collect 7.5 ml of blood from the CTC preservative tube and slowly dispense blood into an appropriately labeled preparation instrument processing tube. 4. Add 6.5 ml of dilution buffer to each sample. Mix by inverting sample 5x. Centrifuge sample at 800 x g for 10 min with the brake in the "off" position. Follow the on-screen instructions on the preparation instrument to load all patient samples onto the system for processing. Samples must be processed within 1 hr of preparation.
Control Preparation for Processing on the Preparation Instrument
1. Gently vortex the control vial and invert 5x to mix. 2. Carefully remove the cap from the control vial and place an inverted preparation instrument processing tube on top of the uncapped vial. In one swift motion, invert the control vial, and pour the contents into the processing tube. While inverted, gently flick the sides of the control vial to release any remaining contents. 3. Carefully remove the inverted control vial from the processing tube, ensuring that no liquid is lost and place aside. Using a 1,000 μl pipette, collect any remaining contents from the vial and lid and gently pipette into the processing tube. 4. Follow the on-screen instructions on the preparation instrument to load the control onto the system for processing.
Sample Scanning on the Analysis Instrument
1. Follow the on-screen instructions on the preparation instrument to unload all samples from the system. Loosely cap each magnetic device cartridge and tap the magnetic device using hands or lab bench to release any bubbles that are stuck to the edges of the cartridge. Once all the bubbles have been removed, firmly cap the cartridge, lay the magnetic device flat, and incubate in the dark for at least 20 min at room temperature. Samples must be scanned within 24 hr of preparation. 2. Turn on the analysis instrument and initialize the lamp. Once warmed (~15 min), load the system verification cartridge onto the analysis instrument and select the QC Test tab. Follow the on-screen instructions to perform the necessary quality control measures. 3. Load a sample onto the analysis instrument and select the Patient Test tab. All saved information from the preparation instrument will be displayed. Click Start to initialize sample scanning. The system will perform a coarse focus and edge detection on the magnetic device cartridge. 4. Adjust all edges as necessary using the directional keys. Select Accept. The system will perform a fine focus and begin sample scanning. 
CTC Characterization for User-defined Markers using the CSS 1. Preparation of User-defined Markers and Instrument Initialization
1. Dilute the antibody of interest using Bond Primary Antibody Diluent to the desired concentration in a marker reagent cup using the following formula, where the working concentration is the concentration of the antibody after addition to the sample and the stock concentration is the concentration of antibody in the reagent cup. For multiple samples, adjust the antibody volumes as described in Table 1 . Place the marker reagent cup into position 1 in the reagent cartridge and load the cartridge onto CSS.
Stock Concentration = (Working Concentration x 850 μl) / 150 μl 2. Collect blood, prepare samples, and load the preparation instrument as described in the above Standard CTC Enumeration from Patient Blood Samples using the CSS protocol. To enable custom marker addition, select User Defined Assay when prompted by the preparation instrument. Input the marker name and select Save. As samples are loaded onto the instrument, the operator will be prompted to indicate which should receive custom marker by selecting Yes or No as necessary. Blood may be processed immediately or stored at room temperature for up to 48 hr following the addition of an equal volume of CytoChex cellular preservative.
Sample Scanning of User-Defined Markers on the Analysis Instrument
1. Remove the sample tubes from the magnet and resuspend in 50 μl of Nucleic Acid Dye, 50 μl of Staining Reagent, 1.5 μl of anti-mouse CD45-APC, 5.0 μl of anti-human HLA-Alexa Fluor 488, and 100 μl of Permeabilization Reagent. For multiple samples, these reagents may be premixed and 206.5 μl of mixture may be added to each tube. Vortex gently to mix and incubate for 20 min at room temperature in the dark. 2. Add 500 μl of dilution buffer, vortex gently, place sample tubes into the magnet, and incubate for 10 min. While the sample tubes are still in the magnet, use a glass pipette to carefully aspirate the residual liquid without touching the wall of the tube next to the magnet and discard.
Remove the sample tubes from the magnet and resuspend in 350 μl of dilution buffer. Vortex gently to mix.
Magnetic Device Loading
1. Using a gel loading tip, carefully transfer the entire volume from the sample tube into a cartridge in the magnetic device. Start at the bottom of the cartridge and slowly withdraw the tip as the sample is dispensed. 2. Once the entire sample has been transferred, loosely cap the magnetic device cartridge and tap the magnetic device using hands or lab bench to release any bubbles that are stuck to the edges of the cartridge as described in Section 3.1 of the Standard CTC Enumeration from Patient Blood Samples using the CSS. 3. Pop any bubbles using a sterile 22 G needle by trapping them between the bevel and the edge of the cartridge. Once all the bubbles have been removed, firmly cap the cartridge, lay the magnetic device flat, and incubate in the dark for at least 10 min. Samples must be scanned within 24 hr of preparation. 
Scanning of Manually Separated Samples on the Analysis Instrument

Representative Results
Standard CTC Enumeration Assay
The sensitivity and specificity of the CSS has been well documented in the literature. However, to validate equivalent CTC recovery, spiked (1,000 LNCaP human prostate cancer cells) and unspiked human blood samples from healthy volunteer donors were processed on the CSS using the standard CSSCTC protocol. As expected, unspiked samples were free of CTCs, 0.00±0.00%, and CTC recovery was demonstrated to be 86.9±4.71% for spiked samples (Figure 1A) . CSS gallery images obtained from spiked samples were of optimal quality and CTCs were easy to distinguish from non-CTCs. However, when processing samples obtained from cancer patients, identification of CTCs is slightly more challenging, with many cells appearing smaller in size and being less easily distinguishable from non-CTCs ( Figure 1B) . In addition, when reviewing patient samples 6 categories of events were identified that were commonly discrepant items between reviewers ( Figure 1C) . These 6 categories included, (1) small events that did not meet the 4 µm size requirement for CTC classification; (2) items with dim CK and/or DAPI staining;
(3) justified (should be counted as a CTC) versus unjustified (should not be counted as a CTC) bleed through into the CD45-APC channel caused by bright CK-PE staining; (4) FITC+ events; (5) pixelated images in the CK and/or DAPI channels; and (6) events with DAPI staining that is larger than CK images or those with DAPI staining that does not overlap >50% with the CK image. For categories (2) and (5) specific criteria exist for CTC classification. For category (2), items with dim CK/DAPI can be classified as CTCs provided that an intact membrane can be observed in the CK channel and an appropriately sized DAPI image is noted. For category (5), items with pixelated CK/DAPI cannot be classified as CTCs if any pixelation is observed in the CK channel. However, pixelation is acceptable in the DAPI channel provided that it is not too severe (i.e. image is entirely white on a background, no grey areas -described by Janssen Diagnostics (formerly Veridex) as white paint on a black background) or diffuse (must still appear oval in shape and fit within the CK).
User-Defined Marker Assay Development
Adaptation of the CSS to characterize CTCs for user-defined markers requires significant work-up with rigorous controls and has been described previously 16 . As a general rule, appropriate optimization of any user-defined marker requires that negative controls be employed to ensure that results are specific. The best results are obtained when spiked samples are processed with both a nonspecific IgG control in place of the target antibody and with the antibody diluent alone as described previously. Various target antibody concentrations and exposure times should also be assessed and validated using cell lines with high, low, and absent (negative) antigen densities. Optimal protocol conditions are achieved when the assay demonstrates both high sensitivity for the target antigen and low background noise from nonspecific binding 16 . An example of this work-up using a cancer stem cell marker, CD44, is presented here. Initial testing with this marker began using the standard CSS CTC kit (hereafter referred to as the traditional CTC kit), which utilizes the FITC channel for user-defined marker development. Using the traditional CTC kit, it was demonstrated that, after significant optimization, the maximum number of CTCs that could be classified as CD44 + was 69.3±2.67% using samples spiked with 1,000 MDA-MB-468 human breast cancer cells, known to demonstrate high CD44 expression with the majority of cells (98.4±0.90%; as determined by flow cytometry) expressing this protein (Figure 2A) . Based upon these findings it was hypothesized that the commercially available CSS CXC kit might produce improved results. This kit allows for improved visualization of markers with a lower antigen density (~50,000 antigens/cell) compared with the traditional CTC kit (optimized for markers with a density of ~100,000 antigens/cell) by reversing the fluorescence channel in which the CK8/18/19 (traditionally represented in the PE channel) and the user's marker of interest (traditionally represented in the FITC channel) are represented (therefore hereafter the CXC kit will be referred to as the low antigen density CTC kit) 26 . After significant optimization, it was demonstrated that this change allowed for improved CD44 staining, with 98.8±0.51% of CTCs classified as CD44 + using CD44-PE at a concentration of 1.0 µg/ml and an exposure time of 0.6 sec (Figure 2A) . Appropriate optimization of any user-defined marker also requires validation using high antigen density (MDA-MB-468), low antigen density (21 NT), and negative (LNCaPs) cell lines for the marker of interest ( Figure 2B ).
CTC Analysis in Preclinical Mouse Models
To determine the sensitivity and specificity of the adapted mouse CSS protocol, spiked (1,000 LNCaP human prostate cancer cells) and unspiked mouse blood samples were processed manually and scanned on the analysis instrument and compared to results obtained using the same cell line processed using the standard automated CSS protocol on the preparation instrument ( Figure 3A) . As expected, unspiked samples were free of CTCs using both assays, 0.00±0.00% and CTC recovery using the adapted mouse kit (90.8±5.18%) was not significantly different from results obtained using the standard automated system (86.9±4.71%; p > 0.05). Images obtained using the manual mouse adapted protocol did not differ from those observed using the standard automated technique, with the exception of the addition of the HLA-FITC marker.
In addition, mouse squamous epithelial cells do not stain positively for HLA-FITC ( Figure 3B ). To confirm that this technique was as sensitive as the standard CSS protocol for the isolation of low number of CTCs, serial dilutions were performed with spiked blood samples and the correlation of expected number of cells versus recovered number of cells was assessed ( Figure 3C) . Results demonstrate that CTCs could effectively be recovered down to a sensitivity of 5 cells/50 µl of whole blood using this assay. These values correlated with expected results with an r 2 = 0.99. 
Discussion
Despite the development of many new CTC technologies since the introduction of the CSS in 2004, this technique is still the only clinically approved technology on the market today and therefore it is considered the current gold standard for CTC detection and enumeration. This manuscript has demonstrated that although the CSS has rigorous quality control standards it can be subject to interpretation bias and that CTC identification in patient samples is much different from identification in spiked samples. Six categories of commonly discrepant items were identified that can cause CTC misclassifications to occur. These discrepant items highlight the need for multiple reviewers on each patient sample processed on this instrument. In addition, the differences observed in spiked versus patient obtained CTCs demonstrates that there is a necessity for any new CTC technologies to be validated in both spiked and patient samples. In addition, these new technologies must be compared to the gold standard CSS using split sample testing of both spiked and patient samples, as efficient CTC capture from spiked samples only does not necessarily reflect CTC capture efficiency in patient samples.
Although the CSS has the capability to perform characterization of captured CTCs, it is quite restricted with regards to highly customizable optimization. In general, the only parameters that can be changed on this instrument for optimization of user-defined markers are the antibody concentration and the length of time that the fluorophore is exposed to the mercury lamp. This limited capacity for optimization can present problems when working-up user-defined markers on the CSS. One solution proposed in this manuscript (described in detail previously 16 ) is the use of the low antigen density CTC kit which switches the FITC and PE fluorescent channels allowing for better visualization of markers with a low antigen density. Regardless of which kit is utilized (traditional-or low antigen density CTC kit) there are several necessary steps that must be undertaken to ensure appropriate marker sensitivity, specificity, and optimization. Firstly, assay sensitivity must be assessed in comparison to a well validated method, such as flow cytometry, that will allow determination of the expected detection level (i.e. the percentage of cells in the cell population that express the marker of interest) of the user-defined marker. Secondly, the assay must be assessed for its ability to detect the marker of interest in cell lines with various levels of expression (i.e. high and low antigen densities) and its specificity must be validated in a cell line that is negative for the marker of interest. In all cases, all cell lines must be tested using a cells only control (no antibody added), the appropriate IgG control, and the antibody of interest at various concentrations and exposure times to determine the most appropriate settings that will ensure optimization of the user-defined marker. However, it should be noted that although characterization of CTCs is possible on the CSS, currently only one user-defined marker of interest can be explored in each sample, and that the system is very limited with regards to downstream applications due to the harsh processing of the samples.
The unique bedside-to-benchtop approach utilized in CTC research has allowed for quick entry of this useful assay into the clinical setting. However, it has resulted in an inadequate understanding of the basic biology of these rare cells. Therefore the development and optimization of assays that allow for assessment of CTCs in preclinical in vivo mouse models of cancer are needed. This manuscript describes an adapted CSS protocol that allows for CTCs to be assessed in 50 µl volumes of mouse blood, ideally suited for serial CTC collection experimental models. This manuscript demonstrates that CTC enumeration using this protocol is comparable to results obtained using the CSS in combination with the traditional CTC kit, with no significant differences in CTC capture efficiency between the automated and manual separation techniques. In addition, during the development of this assay it was recognized, as previously described in the literature 25 , that mouse squamous epithelial cell contamination can make accurate identification of CTCs more difficult and sometimes impossible. Therefore to combat this issue a userdefined HLA-Alexa Fluor 488 was added to this protocol to ensure that only human cells (CK + DAPI + CD45 -HLA -Alexa Fluor 488 + ) are being appropriately assigned as CTCs. It is important to note that the LNCaP cell line used in this manuscript is HLAlow and therefore HLA-Alexa Fluor 488 may need to be titrated for cell lines with varying HLA expression. Although we have added an HLA-Alexa Fluor 488 to our protocol to ensure accurate identification of CTCs, it is noteworthy that the vast majority of mouse squamous epithelial cells were easily identifiable by morphology and were limited in cell number (0.33±0.24 events/50 µl; n = 9). Higher cell numbers (up to 11 events/50 µl) were only observed when blood collection (via cardiac puncture) proved difficult and repeated attempts were necessary. Therefore we propose that if desired, onsystem characterization of CTCs could be accomplished by omitting this marker. In addition, although not described here, we anticipate that collection of CTCs and further downstream characterization of CTCs using other methods could be easily achieved as demonstrated previously using the CSS 27, 28 .
Although the CSS has been utilized clinically to effectively detect CTCs in the blood of metastatic breast, prostate and colorectal cancer patients 4, 10, 29 , it does have several limitations. In up to 35% of patients with various metastatic cancers, CTCs are undetectable despite the presence of widespread systemic disease 30 . This lack of detection has been proposed to be as a result of the epithelial-to-mesenchymal transition, a well-documented process known to enhance cancer invasion, metastasis, and overall aggressiveness 31 . This transition has been associated with a significant reduction in epithelial markers, such as EpCAM, and a corresponding increase in mesenchymal markers 32 . Several studies have recently demonstrated that the presence of these mesenchymal markers in CTCs are indicative of poorer prognosis and that many Copyright © 2014 Journal of Visualized Experiments February 2014 | 84 | e51248 | Page 10 of 11 of these cells lack expression of epithelial markers that would be necessary for their detection using the CSS 24, [33] [34] [35] [36] [37] [38] . This suggests that the standard CSS definition may be missing some of the most aggressive CTCs.
Despite the described limitations, it is anticipated the protocols described in this manuscript will be important tools for improved CTC analysis using the CSS, development of novel CTC technologies, optimization of user-defined markers, and improved understanding of CTC biology using in vivo preclinical mouse models. Taken together, these protocols will provide a useful resource for users of this platform interested in preclinical and clinical research pertaining to metastasis and CTCs.
Disclosures
The author (A.L.A.) received funding that was provided by Janssen Oncology, whose parent company Johnson & Johnson also owns Janssen Diagnostics LLC, which produces reagents and instruments used in this article.
